{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-010713","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.814824+00:00","generated_at":"2026-05-24T03:36:48.629181+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Strata Q4 rev +10% to $9.6M; net loss $4.5M; adj. EBITDA improves to $2.2M in 2024","bullets":["Q4 2024 revenue $9.6M, up 10% from $8.7M; net loss $4.5M (EPS -$1.18 vs -$1.09).","Full-year 2024 revenue $33.6M (flat); net loss $10.1M (EPS -$2.65).","Gross margin improved to 60.1% in Q4 (480 bps YoY); non-GAAP adj. EBITDA $2.2M vs $1.0M.","Domestic XTRAC units reduced to 864; avg rev per device up 6% to $5,906.","International Q4 sales $4.1M (+41% YoY); cash $8.6M at year end."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-010713","json":"https://secwatch.observer/filing/0001140361-25-010713.json","markdown":"https://secwatch.observer/filing/0001140361-25-010713.md","text":"https://secwatch.observer/filing/0001140361-25-010713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036125010713/0001140361-25-010713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036125010713/ef20046329_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:36:48.629181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}